An interventional study of Kinesiology Taping and Diaphragmatic Breathing Exercises in Obesity, sponsored by Elif Kabasakal. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Elif Kabasakal · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 353 studies in Obesity with a site in Turkey, this one is the 154th largest by planned enrollment of the 192 interventional ones that give a count, is one of 54 that started in 2025, is one of 161 with no phase, reaches primary completion later than 14 of the 89 other live ones, and was the 213th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Duzce University · Sites in Turkey
Ages 18+
Pamukkale University · Sites in Turkey
Ages 18–60 · Women only
Kocaeli University · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 54 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 64 across the 192 interventional studies, 82 across the 160 observational. Of the 237 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 353 have an industry lead sponsor. The 10 most frequent:
Elif Kabasakal is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Elif Kabasakal has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 353 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity, defined as excessive fat accumulation, is a chronic, complex, and global health issue. It is increasingly prevalent worldwide and is considered a disease that requires treatment. According to recent data, 43% of adults aged 18 and over were classified as overweight, and 16% as obese. In Turkey, a national health survey reported that among individuals aged 15 and above, 20.2% were obese, and 35.6% were in a pre-obese state based on their body mass index (BMI).
The effects of excess weight on health are significant, as weight gain shortens life expectancy and reduces quality of life. Obesity has detrimental effects on many systems, including the respiratory system. It reduces the compliance of the lungs and chest wall, alters respiratory patterns and ventilation-perfusion relationships, impairs gas exchange, and decreases lung volumes. In some individuals, respiratory control is altered due to the effects of adipokines, which can lead to hypoventilation and increased levels of carbon dioxide in the blood (hypercapnia).
Obesity affects the respiratory system both symptomatically (e.g., shortness of breath) and functionally. Respiratory function disorders in individuals with obesity may include decreased functional residual capacity (FRC), expiratory reserve volume (ERV), and, in some cases, reduced total lung capacity (TLC). Additionally, obesity is a health issue that affects sleep quality. There are three proposed bidirectional relationships: obesity causes poor sleep, poor sleep contributes to obesity, and both may coexist. Individuals with obesity often report poor sleep quality and sleep disorders such as sleep apnea.
The primary function of the respiratory system is gas exchange, which is closely related to the mechanical properties of the respiratory pump. The functionality of this pump depends on the interaction of the lungs, abdominal wall, ribs, intercostal muscles, and the diaphragm. In diseases that impair the structure of the diaphragm, improving its function can alleviate symptoms and significantly enhance pulmonary function test results.
Kinesiology taping (KT), an elastic therapeutic taping method, is commonly used for musculoskeletal disorders but has a wide range of clinical applications. Kinesiology tapes are reported to support weak muscles, increase circulation, reduce pain by stimulating the neurological system, provide proprioceptive feedback, and correct joint misalignments. The mechanism by which KT influences muscle strength depends on the application technique, which can either enhance or inhibit muscle activation. The underlying mechanism is explained by the stimulation of sensory-motor and proprioceptive systems, aiming to improve muscle function through enhanced neuromuscular feedback. Kinesiology taping has also shown potential benefits in respiratory conditions by improving diaphragm function, reducing respiratory muscle fatigue, and enhancing overall respiratory mechanics.
Understanding the effects of thoracic kinesiology taping on respiratory function, vital signs, sleep, quality of life, and cognitive functions in individuals with obesity is of great importance for physiotherapists and researchers. The findings from this study may provide valuable insights for developing comprehensive rehabilitation programs and improving the health status of individuals with obesity. Therefore, the aim of this study is to investigate the effects of thoracic kinesiology taping on respiratory functions, respiratory muscle strength, vital signs, sleep, quality of life, and cognitive status in individuals with obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thoracic kinesiology taping will be applied using 5 cm-wide, latex-free cotton tape following Kase's
Other: Kinesiology Taping
Participants in the control group will receive diaphragmatic breathing exercises. Exercises will be taught and supervised by a physiotherapist. Sessions will be conducted twice weekly for four weeks, and participants will be instructed to continue home practice between sessions.
Other: Diaphragmatic Breathing Exercises
For thoracic kinesiology taping (KT), a 5 cm wide, 100% cotton, latex-free elastic tape will be used. Application sites will follow the technique and principles described by Kase. Participants will sit upright in an armless chair with knees at 90° flexion, feet flat on the floor, and arms relaxed. The tape will be applied to the front and back of the body to facilitate respiratory muscles, primarily the diaphragm. On the anterior side, an "I"-shaped strip will be applied with 50-75% tension at the xiphoid process along the linea alba, and the tails will be laid over the subcostal area without tension. Posteriorly, another "I"-shaped strip will be applied from the projection of the 12th thoracic vertebra with 50-75% tension, and the ends placed toward the ribs without tension. Additionally, two more strips will be applied to the upper trapezius region between the neck and acromion bilaterally.
Participants in the control group will receive diaphragmatic breathing exercises. Exercises will be taught and supervised by a physiotherapist. Sessions will be conducted twice weekly for four weeks, and participants will be instructed to continue home practice between sessions.
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) will be measured using a portable spirometer (Cosmed Pony FX, Italy) following ATS/ERS guidelines. Results will be recorded in liters and as a percentage of the predicted value.
Time frame: At baseline (before the intervention) and at the end of the 4th week of intervention
Forced Expiratory Volume in 1 Second (FEV1)
FEV1 will be assessed using a spirometer (Cosmed Pony FX) under ATS/ERS standards. The measurement will be recorded in liters and as a percentage of the predicted normal value.
Time frame: At baseline (before the intervention) and at the end of the 4th week of intervention
FEV1/FVC Ratio
The ratio of FEV1 to FVC (FEV1/FVC) will be calculated to assess airway obstruction. The values will be expressed as a percentage. All procedures will be carried out with standardized spirometry protocols (ATS/ERS) using single-use mouthpieces and filters.
Time frame: At baseline (before the intervention) and at the end of the 4th week of intervention
Peak Expiratory Flow (PEF)
PEF will be measured as part of the pulmonary function test using a spirometer. Values will be expressed in liters per second (L/s) and as a percentage of the predicted value. Infection control procedures will include the use of disposable mouthpieces and filters as per device guidelines.
Time frame: At baseline (before the intervention) and at the end of the 4th week of intervention
Maximal Inspiratory Pressure (MIP)
Maximal Inspiratory Pressure (MIP) will be measured using a portable electronic mouth pressure device (Micro Medical Micro RPM, UK). The measurement will be performed during maximal inspiratory effort against an occluded airway after full expiration and held for 1-3 seconds. Three trials will be conducted, and the highest value will be recorded. Results will be expressed in cmH₂O and as a percentage of age- and sex-predicted reference values. Infection control procedures will include disposable, single-use mouthpieces and filters.
Time frame: Baseline and Week 4 (Post-Intervention)
Maximal Expiratory Pressure (MEP)
Maximal Expiratory Pressure (MEP) will be assessed using a portable electronic mouth pressure device (Micro Medical Micro RPM, UK). The participant will first perform maximal inspiration, then exhale maximally against an occluded airway for 1-3 seconds. The best of three measurements will be used. Data will be reported in cmH₂O and as a percentage of predicted values based on age and sex. Standard infection control measures with single-use mouthpieces and filters will be followed.
Time frame: Baseline and Week 4 (Post-Intervention)
Pittsburgh Sleep Quality Index (PSQI) Total Score
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-report questionnaire consisting of 19 items grouped into 7 components. Each item is scored from 0 to 3, and the sum of the 7 component scores yields a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality. A total score of ≤5 indicates good sleep quality, while \>5 indicates poor sleep quality. The validated Turkish version will be used in this study.
Time frame: Baseline and Week 4 (Post-Intervention)
Heart Rate (HR)
Heart rate (HR) will be measured in beats per minute (bpm) using a validated digital pulse oximeter or heart rate monitor. Measurements will be taken at baseline and at the end of the 4th week, as well as daily during the intervention period (upon waking, during the day, and before sleep).
Time frame: Baseline, Week 4 (Post-Intervention), and Daily During Weeks 1-4
Oxygen Saturation (SpO₂)
Peripheral oxygen saturation (SpO₂) will be assessed using a digital pulse oximeter. Measurements will be recorded as a percentage and monitored daily during the intervention period, including morning, daytime, and pre-sleep values, along with baseline and end-of-intervention readings.
Time frame: Baseline, Week 4 (Post-Intervention), and Daily During Weeks 1-4
Blood Pressure (Systolic and Diastolic)
Systolic and diastolic blood pressure (BP) will be measured in mmHg using an automated upper-arm digital sphygmomanometer. Readings will be obtained at baseline and at the end of Week 4, as well as daily throughout the intervention (morning, daytime, and before bedtime).
Time frame: Baseline, Week 4 (Post-Intervention), and Daily During Weeks 1-4
Obesity-Specific Quality of Life Questionnaire (OQOLQ) Total Score
Obesity-specific quality of life will be assessed using the OQOLQ, a validated 17-item scale developed by Patrick et al. Each item is scored on a six-point Likert scale. The scale is unidimensional, and higher total scores indicate poorer quality of life. The validated Turkish version will be used in this study.
Time frame: Baseline and Week 4 (Post-Intervention)
Auditory-Visual Number Sequence Test (GİSDT) Total Score
Cognitive function, particularly short-term memory, attention, and concentration, will be assessed using the Auditory-Visual Number Sequence Test (GİSDT). The test includes four subtests: Auditory-Verbal, Visual-Verbal, Auditory-Written, and Visual-Written. Participants are presented with number sequences that increase in length, either by hearing or seeing them, and are required to repeat them in the same order, either verbally or in writing. The score reflects the longest sequence correctly recalled without error in one of two attempts. The Turkish standardized version will be used.
Time frame: Baseline and Week 4 (Post-Intervention)
Ran from May 2025 to primary completion in Aug 2025, 3 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 3 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.